J. Fermont

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

The capability set for work – correlates of sustainable employability in workers with multiple sclerosis

J. J. Van der Klink, H. Middelkoop, P. Jongen, 2018, Health and Quality of Life Outcomes.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Disease impact in chronic progressive external ophthalmoplegia: More than meets the eye

G. Bleijenberg, B. Engelen, J. Kalkman, 2011, Neuromuscular Disorders.

Coping strategies in relation to negative work events and accommodations in employed multiple sclerosis patients

W. Verhagen, K. van der Hiele, J.J.J. van Eijk, 2016, Multiple sclerosis journal - experimental, translational and clinical.

Prevalence and distribution of fasciculations in healthy adults: Effect of age, caffeine consumption and exercise

M. Zwarts, S. Overeem, H. J. Schelhaas, 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.